Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide
NCT01543919
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Male or female subjects between, and including, the ages of 40 and 80 years.
- Subjects with a diagnosis, for at least 6 months, of moderate to severe COPD (GOLD) and who meet the criteria for Stage II-III disease: Subjects must have a post-bronchodilator FEV1/FVC ratio <0.7 and a post-bronchodilator FEV1 of 30 - 80% (inclusive) of the predicted value for age, height, race and sex using European Community for Coal and Steel ECCS standards or NHANES III standards.
- Subjects must have a smoking history of at least 10 pack-years* and meet one of the following criteria: They are current smokers, or they are ex-smokers who have abstained from smoking for at least 6 months.
- Subjects treated with tiotropium bromide (SPIRIVA HandiHaler) 18 microgram daily for at least 1 month prior to screening.
- Subjects must have had stable disease for at least 1 month prior to screening. During the screening and run-in phase subjects must be able to manage disease symptoms adequately with tiotropium bromide +/- salbutamol (albuterol) rescue medication (subjects should not use >10 actuations [100 microgram/actuations] daily for more than 2 consecutive days), without reliance on other therapies including oral or inhaled corticosteroids, other long-acting bronchodilators, nebulizer therapy, theophylline, roflumilast or regular oxygen.
- A COPD exacerbation requiring treatment with oral steroids or hospitalization for the
treatment of COPD within 3 months of screening.
- History of a lower respiratory tract infection or significant disease instability
during the month preceding screening or during the time between screening and
randomization.
- History or presence of respiratory failure, cor pulmonale or right ventricular
failure.
- Subjects with home oxygen therapy (either PRN or long-term oxygen therapy).
- Any clearly documented history of adult asthma or other chronic respiratory disorders
(eg, bronchiectasis, pulmonary fibrosis, pneumoconiosis).
- Known previous diagnosis of Hepatitis B or C or HIV infection (specific screening is
not required).
- History of cancer (other than cutaneous basal cell) in the previous 5 years.
- Active or past history of GI hemorrhage of any etiology, peptic ulceration, erosive
esophagitis, gastric outlet obstruction or inflammatory bowel disease.
- Regular use of aspirin at a dose greater than 325 mg/day.
- History within the previous 6 months of: myocardial infarction, cardiac arrhythmia
(eg, atrial fibrillation, paroxysmal atrial fibrillation, atrial flutter,
supraventricular tachycardia, ventricular tachycardia), left ventricular failure,
unstable angina, coronary angioplasty, coronary artery bypass grafting (CABG) or
cerebrovascular accident (including transient ischemic attacks).
- A family history of long QT syndrome.
- Presenting with: Any condition possibly affecting oral drug absorption (eg,
gastrectomy or clinically significant diabetic gastroenteropathy).
- Any clinically significant skin lesions as described in Common Terminology Criteria
for Adverse Events for Dermatology (CTCAE) Version 3.0.
- Any clinically significant active systemic or cutaneous infection including herpetic
lesions.
- Congestive heart failure requiring treatment New York Heart Association (NYHA) Class
III-IV.
- ECG abnormalities at screening or randomization, including those listed below:
Subjects with pre-randomization evidence of QTcF prolongation (defined as >450 ms) at
screening or baseline (Week 0) are not eligible for randomization. This assessment is
based on a confirmed mean of the triplicate ECG recordings and is made by the
investigator at the time of ECG collection.
- Predominant heart rhythm other than normal sinus rhythm eg, atrial fibrillation,
atrial flutter, supraventricular tachycardia.
- Atrioventricular (AV) block greater than first degree.
- Resting heart rate >100 or <40 bpm.
- Evidence of previous myocardial infarction in the absence of clinical history
consistent with these findings.
- Evidence of acute ischemia.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Birmingham, Alabama
- Jasper, Alabama
- Torrance, California
- Hartford, Connecticut
- Springfield, Illinois
- Muncie, Indiana
- Livonia, Michigan
- Lebanon, New Hampshire
- Charlotte, North Carolina
- Pittsburgh, Pennsylvania
- Spartanburg, South Carolina
- Kingston, Ontario
- Montreal, Quebec
- Montreal, Quebec
- Ste-Foy, Quebec
- Amherstburg, Ontario
- Chatham, Ontario
- Harrow, Ontario
- Leamington, Ontario
- Andrychow,
- Bialystok,
- Bialystok,
- Bialystok,
- Bialystok,
- Bialystok,
- Bielsko-Biala,
- Bielsko-Biala,
- Bielsko-Biala,
- Biskupiec,
- Bochnia,
- Brzesko,
- Brzesko,
- Brzeziny,
- Brzozow,
- Bydgoszcz,
- Bydgoszcz,
- Bydgoszcz,
- Bydgoszcz,
- Bydgoszcz,
- Chelmsko Slaskie,
- Chelm,
- Chelm,
- Chodziez,
- Chojnice,
- Chorzow,
- Chorzow,
- Ciechanow,
- Czarnkow,
- Czestochowa,
- Czestochowa,
- Dabrowa Gornicza,
- Domaradz,
- Dziergowice,
- Gdansk,
- Gdansk,
- Gdansk,
- Gdansk,
- Gdansk,
- Gdansk,
- Gdansk,
- Gdansk,
- Gdynia,
- Gliwice,
- Glucholazy,
- Gora,
- Gorzow Wielkopolski,
- Grodzisk Mazowiecki,
- Grodzisk Mazowiecki,
- Gryfice,
- Jaroslaw,
- Jaslo,
- Jaslo,
- Jaslo,
- Jedrzejow,
- Jelenia Gora,
- Katowice,
- Katowice,
- Katowice,
- Katowice,
- Kcynia,
- Kielce,
- Kielce,
- Kielce,
- Klodzko,
- Kolobrzeg,
- Konin,
- Konskie,
- Konskie,
- Koszalin,
- Koszalin,
- Krakow,
- Krakow,
- Krakow,
- Krakow,
- Krakow,
- Krakow,
- Krakow,
- Krakow,
- Krakow,
- Krasnik,
- Krasnik,
- Krasnik,
- Krosno,
- Kutno,
- Ledziny,
- Legionowo,
- Lisnik Duzy,
- Lodz,
- Lodz,
- Lodz,
- Lodz,
- Lodz,
- Lomza,
- Lomza,
- Lowicz,
- Luban,
- Lubartow,
- Lubin,
- Lubin,
- Lubin,
- Lubliniec,
- Lublin,
- Lublin,
- Lublin,
- Lublin,
- Lubon,
- Ludwikowo,
- Lukow,
- Makow Mazowiecki,
- Malbork,
- Mielec,
- Milicz,
- Myslowice,
- Myszkow,
- Nisko,
- Nowy Dwor Gdanski,
- Nowy Sacz,
- Olawa,
- Olecko,
- Olsztyn,
- Opatow,
- Ostrowiec Swietokrzyski,
- Ostrowiec Swietokrzyski,
- Pabianice,
- Papowo Biskupie,
- Pawonkow,
- Piekary Slaskie,
- Pietrzykowice,
- Pila,
- Piotrkow Trybunalski,
- Plock,
- Pniewy,
- Poniatowa,
- Poznan,
- Poznan,
- Poznan,
- Poznan,
- Poznan,
- Prabuty,
- Proszowice,
- Pruszcz Gdanski,
- Przemysl,
- Rabka Zdroj,
- Radom,
- Radom,
- Ruda Slaska,
- Ruda Slaska,
- Ruda Slaska,
- Ruda Slaska,
- Rumia,
- Rumia,
- Rumia,
- Rybnik,
- Rybnik,
- Rybnik,
- Rzeszow,
- Rzeszow,
- Sanok,
- Sawin,
- Sejny,
- Siewierz,
- Skarzysko Kamienna,
- Skawina,
- Skoczow,
- Skrzyszow,
- Slawno,
- Slubice,
- Slupca,
- Sokolowsko,
- Sopot,
- Sosnowiec,
- Sosnowiec,
- Srem,
- Srem,
- Stalowa Wola,
- Starachowice,
- Starachowice,
- Stargard Szczecinski,
- Sucha Beskidzka,
- Suprasl,
- Suwalki,
- Suwalki,
- Swidnik,
- Swiecie,
- Sycow,
- Szczecinek,
- Szczecin,
- Szczecin,
- Szczecin,
- Szczecin,
- Szczecin,
- Tarnobrzeg,
- Tarnobrzeg,
- Tarnowskie Gory,
- Tarnow,
- Tarnow,
- Torun,
- Torun,
- Torun,
- Trzcianka Lubuska,
- Twardogora,
- Tychy,
- Tychy,
- Uchanie,
- Walcz,
- Warszawa,
- Warszawa,
- Warszawa,
- Warszawa,
- Warszawa,
- Warszawa,
- Warszawa,
- Warszawa,
- Warszawa,
- Warszawa,
- Warszawa,
- Warszawa,
- Warszawa,
- Warszawa,
- Warszawa,
- Wejherowo,
- Wieliczna,
- Wielun,
- Witonia,
- Wloc³awek,
- Wodzislaw Slaski,
- Wolomin,
- Wroclaw,
- Wroclaw,
- Wroclaw,
- Wroclaw,
- Wroclaw,
- Wroclaw,
- Wroclaw,
- Zabkowice Slaskie,
- Zabkowice Slaskie,
- Zabrze,
- Zabrze,
- Zabrze,
- Zagoty,
- Zblewo,
- Zgierz,
- Zielona Gora,
- Zielona Gora,
- Zielonka k/Warszawy,
- Zyrardow,
- Birmingham, Alabama
- Birmingham, Alabama
- Jasper, Alabama
- Palo Alto, California
- San Diego, California
- Lexington, Kentucky
- Baltimore, Maryland
- Bloomington, Minnesota
- Rochester, Minnesota
- Omaha, Nebraska
- Albuquerque, New Mexico
- Rochester, New York
- Charlotte, North Carolina
- Cincinnati, Ohio
- Pittsburgh, Pennsylvania
- Kingsport, Tennessee
- Clarksburg, West Virginia
- Gilly,
- Leuven,
- Menen,
- Yvoir,
- Vancouver, British Columbia
- Kingston, Ontario
- Toronto, Ontario
- Ste-Foy, Quebec
- Cvikov,
- Hradec Kralove,
- Karlovy Vary,
- Liberec,
- Neratovice,
- Pardubice,
- Praha 10,
- Praha 3,
- Praha 6,
- Strakonice,
- Tabor,
- Usti nad Labem,
- Berlin,
- Berlin,
- Gelnhausen,
- Rüdersdorf,
- Ulm,
- Athens,
- Athens,
- Thessaloniki,
- Enschede,
- Etten Leur,
- Spijkenisse,
- Zutphen,
- Amadora,
- Coimbra,
- Lisboa,
- Dnipropetrovsk,
- Kharkiv,
- Kharkov,
- Kharkov,
- Kiev,
- Kiev,
- Simferopol,
- Garston, Watford,
- Harrow,
- Warminster,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide | |||
Official Title ICMJE | A Phase 2B, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Once-Daily Orally Administered PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide | |||
Brief Summary | PH-797804 is an oral anti-inflammatory drug that may reduce the inflammation that is associated with Chronic Obstructive Pulmonary Disease (COPD). PH-797804 will be dosed to patients with Chronic Obstructive Pulmonary Disease (COPD) to evaluate its potential safety and efficacy profile in Chronic Obstructive Pulmonary Disease (COPD) | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 2 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment | |||
Condition ICMJE | Pulmonary Disease, Chronic Obstructive | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 730 | |||
Original Estimated Enrollment ICMJE | 660 | |||
Actual Study Completion Date ICMJE | September 2013 | |||
Actual Primary Completion Date | September 2013 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 40 Years to 80 Years (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Argentina, Bulgaria, Canada, Czech Republic, Germany, Hungary, Japan, Poland, Slovakia, South Africa, Spain, Sweden, Taiwan, United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT01543919 | |||
Other Study ID Numbers ICMJE | A6631033 | |||
Has Data Monitoring Committee | Yes | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Pfizer | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | September 2014 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |